In these contexts, PDK4 activates HDAC8 by phosphorylating the Ser-39 site of nuclear HDAC8, which deacetylates and inhibits the expression of CD20 protein, inducing rituximab resistance in DLBCL cells. Here, PDK4 is linked to diffuse large B-cell lymphoma.